Slide 1: Conference Call Preliminary FY 2016 Results
Conference Call Preliminary FY 2016 Results Joachim Kreuzburg, CEO | January 30, 2017
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda 01 Sartorius Group: FY 2016 Results | 2017 Guidance 02 Sartorius Stedim Biotech Group: FY 2016 Results | 2017 Guidance 03 Questions & Answers
Slide 4: FY 2016 Highlights
FY 2016 Highlights Continued double-digit sales and earnings growth in line with guidance Outstanding performance of Bioprocess Solutions fueled by strong market growth and ongoing market share gains esp. in the Americas Positive business development of Lab Products & Services; Portfolio for Biophar
Slide 5: Continued Strong Growth Momentum
Continued Strong Growth Momentum Sartorius Group in millions of € unless otherwise specified FY 2015 FY 2016 in % in % cc 1 Sales revenue 1,114.8 1,300.3 +16.6 +18.2 Order intake 1,172.7 1,334.7 +13.8 +15.3 Underlying EBITDA2 263.2 325.4 +23.6 Underlying EBITDA2 margin in % 23.6 25.0 Underlying EPS
Slide 6: Broad-based Business Expansion
Broad-based Business Expansion Americas EMEA Asia | Pacific Sales by Region € in millions € in millions € in millions in % 569.1 EMEA ~ 44% 505.5 445.4 371.7 Americas ~ 34% 285.8 237.6 ~ € 1.3bn Asia | Pacific ~ 22% FY 15 FY 16 FY 15 FY 16 FY 15 FY 16 +21.0 % +14.7 % +21.2 % Acc. to customers‘ locat
Slide 7: BPS: Excellent Performance in Line with Upgraded Expectations
BPS: Excellent Performance in Line with Upgraded Expectations Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +17.2% cc +22.1% cc +27.5% +15.7% +20.5% 1.006,5 975.0 273.5 869.9 809.2 214.5 28.0% 26.5% FY 15 FY 16 FY 15 FY 16 FY 15 FY 16 Double-digit
Slide 8: LPS: Positive Business Development in Line with Expectations
LPS: Positive Business Development in Line with Expectations Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +9.9% cc +7.9% cc +6.5% +8.4% +6.5% 328.1 305.5 325.3 51.9 302.8 48.8 16.0% 16.0% FY 15 FY 16 FY 15 FY 16 FY 15 FY 16 Robust organic growth d
Slide 9: Healthy Cash Flow Development
Healthy Cash Flow Development Sartorius Group € in millions FY 2015 FY 2016 in % Extraordinary items reflect various cross-divisional projects and Underlying EBITDA 263.2 325.4 23.6 expenditures related to the recent Extraordinary items -12.6 -30.7 -143.7 acquisitions Reported prior-year net pro
Slide 10: Financial Position Remains Strong Despite Recent Acquisitions
Financial Position Remains Strong Despite Recent Acquisitions Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2015 Dec. 31, 2016 600 3.0 3 480 2.4 2,4 Equity ratio in % 44.9 42.0 360 1.8 1,8 Net debt in millions of € 344.0 485.9 240 1.2 1,2 120 0.6 0,6 Net debt | unde
Slide 11: Outlook for 2017
Outlook for 2017 FY 2016 FY 2017 Guidance1 Sales Revenue Underlying Sales Revenue Underlying Growth1 EBITDA Margin Growth EBITDA Margin Sartorius Group 18.2% 25.0% ~ 8% - 12% ~ +0.5pp Bioprocess Solutions 22.1% 28.0% ~ 9% - 13% ~ +0.5pp Lab Products & Services 7.9% 16.0% ~ 6% - 10% ~ +1.0pp 1 In con
Slide 12: Agenda
Agenda 01 Sartorius Group: FY 2016 Results | 2017 Guidance 02 Sartorius Stedim Biotech Group: FY 2016 Results | 2017 Guidance 03 Questions & Answers
Slide 13: Excellent Development in Line with Upgraded Expectations
Excellent Development in Line with Upgraded Expectations Sartorius Stedim Biotech Group in millions of € unless otherwise specified FY 2015 FY 2016 in % in % cc 1 Sales revenue 884.3 1,051.6 +18.9 +20.4 Order intake 946.4 1,080.8 +14.2 +15.6 Underlying EBITDA2 231.3 288.7 +24.8 Underlying EBITDA2 ma
Slide 14: Double-digit Growth in All Regions
Double-digit Growth in All Regions Americas EMEA Asia | Pacific Sales by Regions in € millions in € millions in € millions in % 454.4 387.8 397.2 EMEA ~ 43% 323.5 209.5 163.7 Americas ~ 37% € 1.05bn FY 15 FY 16 FY 15 FY 16 FY 15 FY 16 +21.0% +16.5% +29.0% Asia | Pacific ~ 20% Acc. to customers‘ loca
Slide 15: Healthy Cash Flow Performance; Influenced by Acquisitions
Healthy Cash Flow Performance; Influenced by Acquisitions Sartorius Stedim Biotech Group € in millions FY 2015 FY 2016 in % Extraordinary items reflect various corporate projects and expenditures Underlying EBITDA 231.3 288.7 +24.8 related to the recent acquisitions Extraordinary items -7.4 -18.1
Slide 16: Financial Position Remains Very Strong
Financial Position Remains Very Strong Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2015 Dec. 31, 2016 150 1.5 1,5 1.5 Equity ratio in % 60.7 63.9 120 1.2 1.2 1,2 90 0.9 0,9 0.9 Net debt in millions of € 86.4 67.6 60 0.6 0,6 0.6 30 0.3 0.3 0,3 Net debt | u
Slide 17: Outlook for 2017
Outlook for 2017 FY 2016 FY 2017 Guidance Sales revenue growth1 20.4% ~ 8% - 12% Underlying EBITDA margin 27.5% ~ +0.5pp1 Capex ratio 7.6% ~ 10% - 13% 1 In constant currencies 17
Slide 18: Agenda
Agenda 01 Sartorius Group: FY 2016 Results | 2017 Guidance 02 Sartorius Stedim Biotech Group: FY 2016 Results | 2017 Guidance 03 Questions & Answers
Slide 19: Thank you very much for your attention
Thank you very much for your attention